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Abstract
Aims Mild or moderate aortic regurgitation (AR) has only little effect on cardiovascular outcome in people with normal left
ventricular ejection fraction (EF); therefore, it is not perceived as a major clinical problem. This study investigates whether mild
or moderate AR is associated with increased short‐term mortality in patients hospitalized for treatment of acute heart failure
(AHF) and whether mild or moderate AR impacts differently on short‐term mortality in AHF patients with reduced EF (AHFrEF),
mid‐range EF (AHFmrEF), or preserved EF (AHFpEF).
Methods and results This mono‐centric study included 505 consecutive adult patients hospitalized for de novo or worsening
chronic HF not related to acute ischaemia or severe valvular pathology in the echocardiogram at index hospitalization. Cox re-
gression analysis studied the impact of AR on all‐cause mortality (ACM) over the 150 days’ study period. Mild or moderate AR
was associated with increased ACM (HR 1.75 [95% CI: 1.1–2.7]; P¼ 0.009). The prevalence of mild or moderate AR in the study
population was 42% and not significantly different between AHFpEF (n ¼ 227), AHFmrEF (n ¼ 86), and AHFrEF (n ¼ 192) study
participants (37.9% vs. 50.0% vs. 42.7%; P ¼ 0.144). In AHFpEF patients, the age‐adjusted hazard for ACM was increased in
patients with AR compared with patients without AR (HR 2.17 [95% CI: 1.1–4.2]; P ¼ 0.002). The age‐adjusted hazard for
ACM was increased by a trend in AHFmrEF with AR (HR 7.11, [95% CI: 0.9–57.8]; P ¼ 0.067) and not different between the
AHFrEF groups (HR 0.95 [95% CI: 0.5–1.8]; P ¼ 0.875).
Conclusions Mild or moderate AR increased ACM only in AHFpEF patients, highlighting a distinct clinical relevance.
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Introduction
Epidemiological studies show that the low prevalence of aor-
tic valve insufficiency at younger age increases to a 13–29%
level in the elderly.1–3 A similar increase has been shown
for the prevalence of symptomatic heart failure (HF) in the
general population, which is low at younger age but affects
>40% of people at the age of 70 years and above.4,5 This sug-
gests that coincidence of aortic regurgitation (AR) and HF
should occur in particular in the aged.
For patients with symptomatic and asymptomatic severe
AR with or without reduced left ventricular ejection fraction
(LVEF), the therapeutic strategy is set out.6 However, the clin-
ical importance of mild or moderate AR remains unclear in
particular in HF, although about 20% of hospitalized patients
with non‐severe AR have also HF as shown in a more recent
epidemiological hospital‐based survey.7
We therefore studied the impact of mild or moderate AR
on all‐cause mortality (ACM) in patients with hospitalization
for treatment of acute HF (AHF). This study population was
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chosen because acute decompensation represents a fair ar-
gument for the presence of HF, which can be difficult to diag-
nose in particular when LVEF is in the mid‐range or
preserved.8,9 In fact, this approach has already been success-
fully adopted in an earlier study investigating characteristics
of the HF patients with preserved LVEF.10 Another argument
in favour of application of the research question to these
patients is their high burden of adverse cardiovascular out-
come. In theory, the latter should permit detection of interac-
tion even in smaller‐size groups with short‐term follow‐up.
Methods
Study population
This study combines two local prospective registries (years
2005–2009, n ¼ 402; years 2015–2018, n ¼ 221).11,12 Both
registries had prospectively recruited consecutive adult AHF
patients with presentation to the emergency wards followed
by hospitalization at the Lausanne University Hospital.
Screening excluded patients with exacerbation of obstructive
pulmonary disease, acute pulmonary embolism or
stress‐related cardiomyopathy, acute myocardial ischaemia,
or acute mechanical cause from acute coronary syndrome;
patients after recent cardiac surgery; or patients with echo-
cardiography performed short term before hospitalization.9
Inclusion criteria were (i) age ≥ 18 years; (ii) hospitalization
for AHF treatment at the CHUV; (iii) transthoracic echocardio-
graphic exam during index hospitalization; and (iv) written
consent. Additional exclusion criteria were (i) pregnancy; (ii)
comorbidity with survival time considered to be <1 year on
the basis of the patient’s medical history including primary
pulmonary artery hypertension; (iii) severe aortic, mitral,
and tricuspid regurgitation or stenosis on index echocardiog-
raphy; (iv) AHF caused by acute metabolic, toxic or infectious
disorders; (v) AHF with accompanying cerebrovascular insult;
and (ii) prior aortic valve replacement. The study protocol
was approved by the local ethics committee (CER Vaud
2019–01158).
Acquisition of anthropometric, biological, and
clinical data
Anthropometric, biological, clinical admission data and medi-
cal history were collected from the individual patients’ elec-
tronic health report at the Lausanne University Hospital
(T. A., G. T., and N. S.). Data accuracy was tested by revisiting
30% of randomly selected patients’ data revealing 99.7% cor-
rectness (T. A. and N. S.). Standard transthoracic echocardio-
graphic images and parameters were acquired by
board‐certified cardiologists. Echocardiographic analysis was
performed offline using EchoPac software, version 4.0.4 (GE
Medical Systems) (G. T., N. B., J. R., and P. M.). LVEF was
assessed using the Simpson method; the severity of valvular
regurgitations was graded using a multiparametric assess-
ment as recommended by the European Association of Car-
diovascular Imaging.13,14
Types of heart failure
Participants were classified to suffer from chronic HF (CHF)
when presenting clinical signs of CHF before index admission
as documented in the patients’ history. Patients were classi-
fied to have AHF with preserved EF (AHFpEF) when LVEF
was ≥50%, AHF with mid‐range EF (AHFmrEF) when LVEF
was ≥40–49%, and AHF with reduced EF (AHFrEF) when LVEF
was <40% in analogy to the European Society of Cardiology
guidelines for the diagnosis and treatment of AHF and CHF.8
Study outcome: all‐cause mortality over the
study period of 150 days after hospital admission
for treatment of decompensated heart failure
ACM was seized over a 150 days’ period starting on the day
of hospital admission; 99.8% of study patients had a length
of hospital stay < 30 days.
Statistical analysis
Analyses were performed with Stata® 13.1 (StataCorp, Col-
lege Station, TX, USA). As normal distribution could not be en-
sured for most of the variables, all continuous variables are
shown as medians with inter‐quartile ranges. Categorical var-
iables were shown as per cent (absolute number).
Associations with AR were tested using the Mann–Whitney
U‐test for continuous variables and the χ2 test for categorical
variables. The Kruskal–Wallis test with the Mann–Whitney U‐
test and the χ2 as a post‐hoc test were performed to com-
pare interval variables with categorical variables between
the three different types of HF.
Cox regression analysis was used to identify parameters
that were associated with ACM over the study period. The
hazard ratio (HR) accompanied by its 95% CI was used as a
measure of strength for Cox regression analysis results.
Variables that showed at least very weak evidence
(P < 0.2) for an association with type of HF (Tables S1
and S2), mild or moderate AR, and ACM were included in
the multivariable Cox regression analysis to study the im-
pact of mild or moderate AR on ACM according to the type
of HF. Thus, an interaction term between type of HF and AR
was forced in the multivariable model. To get to the final
model, covariables with a non‐significant P‐value
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(P > 0.05) were removed in a stepwise backward approach.
The test of proportional hazards assumption was used for
the final model to test the prerequisite to use a Cox regres-
sion model.
Results
Screening and inclusion into the study population
Screening excluded myocardial ischaemia (n ¼ 129) and
echocardiography at short term before index hospitalization
(n ¼ 118). Thirty patients were excluded after initial inclusion
because of severe valvular pathology at index echocardiogra-
phy; 34 patients were excluded because of severe
non‐cardiac pathology suspected to impact on short‐term
mortality. Five hundred five study participants were retained
for the final analysis (cohort 2005–2009 and 2015–2018,
n ¼ 311 and n ¼ 194, respectively).
Demographic, clinical, medical, and biological
characteristics of acute heart failure patients
without or with mild or moderate aortic
regurgitation
The prevalence of mild or moderate AR was 42% (211/505) in
this study population; 43% (216/505) were female; 52% (261/
505) had a history of previous myocardial infarction.
AR patients were older (80.5 [74.2–85.7] vs. 77.8 [68.7–
84.3] years; P ¼ 0.002), the body mass index (BMI) was lower
(25.8 [23.5–31.1] vs. 26.9 [24–31.6]; P ¼ 0.014), and diabetes
and smoking were less prevalent (62 [29.4%] vs. 133 [45.2%],
P < 0.001; 103 [48.8%] vs. 173 [59%], P ¼ 0.023). All other
cardiovascular risk factors were not significantly different be-
tween groups (Table 1). Patients with AR were less frequently
implanted with an internal cardiac defibrillator (8 [3.8%] vs.
25 [8.5%], P ¼ 0.035), treated with statins (77 [36.7%] vs.
134 [45.7%], P ¼ 0.042), oral antidiabetics (26 [12.4%] vs.
59 [20.1%], P ¼ 0.023), or insulin (27 [12.9%] vs. 64
[21.8%], P ¼ 0.01) (Table 1). The serum glucose level was
lower at admission in patients without AR (6.8 [5.9–8.4] vs.
Table 1 Demographic and clinical characteristics of acute heart failure patients without or with mild or moderate aortic regurgitation
n All (n ¼ 505) Patients with AR (n ¼ 211) Patients without AR (n ¼ 294) P‐value
Demographic and clinical parameters
Age (years) 505 79.3 [71–85] 80.5 [74.2–85.7] 77.8 [68.7–84.3] 0.002
Female gender (%) 505 216 (42.8) 96 (45.5) 120 (40.8) 0.29
BMI (kg/m2) 504 26.4 [23.5–31.1] 25.8 [22.8–30.1] 26.9 [24–31.6] 0.014
SBP (mmHg) admission 505 136 [120–156] 137 [120–160] 136 [120–156] 0.711
SBP (mmHg) discharge 500 124 [109–138] 126 [109–135] 124 [109–140] 0.573
DBP (mmHg) admission 505 80 [68–90] 80 [68–92] 79 [68–90] 0.281
DBP (mmHg) discharge 499 66 [58–75] 66 [57–74] 67 [59–76] 0.101
HR (b.p.m.) admission 505 89 [75–107] 88 [71–107] 90 [75–107] 0.751
HR (b.p.m.) discharge 499 75 [65–85] 74 [65–84] 75 [66–85] 0.21
Co‐morbidity
COPD (%) 505 84 (16.6) 28 (13.3) 56 (19.0) 0.086
Smoking status (%) 504 276 (54.8) 103 (48.8) 173 (59.0) 0.023
Hx of Afib/flutter (%) 505 284 (56.2) 129 (61.1) 155 (52.7) 0.06
Hx of MI (%) 505 261 (51.7) 105 (49.8) 156 (53.1) 0.464
Dyslipidaemia (%) 502 293 (58.4) 118 (56.5) 175 (59.7) 0.464
Hypertension (%) 505 422 (83.6) 177 (83.9) 245 (83.3) 0.869
Diabetes mellitus (%) 505 195 (38.6) 62 (29.4) 133 (45.2) <0.001
QRS duration (ms) 505 98.0 [80–120] 100.0 [80–120] 92.0 [80–120] 0.304
Medical therapy
ICD (%) 505 33 (6.5) 8 (3.8) 25 (8.5) 0.035
Pacemaker (%) 505 57 (11.3) 25 (11.8) 32 (10.9) 0.736
Statin (%) 503 211 (41.9) 77 (36.7) 134 (45.7) 0.042
Beta‐blocker (%) 505 247 (48.9) 100 (47.4) 147 (50.0) 0.563
ACEI (%) 505 183 (36.2) 80 (37.9) 103 (35.0) 0.507
ARB (%) 505 145 (28.7) 56 (26.5) 89 (30.3) 0.361
ARNI (%) 505 1 (0.2) 0 (0.0) 1 (0.3) 0.396
MRA (%) 505 78 (15.4) 36 (17.1) 42 (14.3) 0.395
Loop diuretic (%) 505 292 (57.8) 123 (58.3) 169 (57.5) 0.856
Antidiabetic drug (%) 504 85 (16.9) 26 (12.4) 59 (20.1) 0.023
Insulin (%) 504 91 (18.1) 27 (12.9) 64 (21.8) 0.01
ACEI, angiotensin‐converting enzyme inhibitor; AR, aortic regurgitation of mild or moderate severity; ARB, angiotensin receptor blocker;
ARNI, angiotensin II receptor blocker neprilysin inhibitor; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DBP, dia-
stolic blood pressure; Hx of Afib/flutter, history of persistent/paroxysmal/permanent atrial fibrillation or flutter; Hx of HF, history of heart
failure; Hx of MI, history of myocardial infarction; ICD, implantable cardioverter defibrillator; LADi, left atrium diameter index; LVEDDi, left
ventricular end‐diastolic diameter index; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; MRA, mineralocorticoid
receptor antagonist; SBP, systolic blood pressure.
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7.4 [6.0–10.1] mmol/L, P ¼ 0.041). Electrolytes, renal func-
tion, and haematological parameters were not significantly
different between patients with or without AR (Table 2).
Echocardiographic characteristics of acute heart
failure patients without or with mild or moderate
aortic regurgitation
Patients with AR had a larger indexed LV end‐diastolic
diameter (LVEDD) (30 [27–34] vs. 28.2 [25–32] mm/m2,
P ¼ 0.004); LV mass index was higher (120 [93–144] vs.
109 [86–132] g/m2, P ¼ 0.004). The prevalence of mild or
moderate mitral regurgitation (MR) (91.4% [n ¼ 192] vs.
76.5% [n ¼ 225], P < 0.001) and tricuspid regurgitation
(85.2% [n ¼ 178] vs. 73.8% [n ¼ 217], P ¼ 0.002) was
higher in patients with AR. Mild or moderate aortic stenosis
with or without AR was not significantly different between
both groups (14.7% [n ¼ 31] vs. 15.0% [n ¼ 44],
P ¼ 0.932) (Table 3).
Parameters associated with all‐cause mortality in
univariable Cox regression analysis
Parameters that were associated ACM over the study period
(P < 0.05) were dyslipidaemia (HR 0.44 [0.29–0.67],
P < 0.001), BMI per kg/m2 (HR 0.92 [0.89–0.96], P < 0.001),
systolic blood pressure at admission per mmHg (HR 0.99
[0.98–0.99], P ¼ 0.004), age per year (HR 1.04 [1.01–1.06],
P ¼ 0.002), mild or moderate AR (HR 1.75 [1.15–2.66],
P ¼ 0.009), HFmrEF (HR 0.38 [0.18–0.82], P ¼ 0.013 com-
pared with HFrEF), pacemaker (HR 1.26 [1.08–3.2],
P ¼ 0.025), red cell distribution width per % (HR 1.08
[1.01–1.15], P ¼ 0.029), mineralocorticoid receptor antago-
nist treatment (HR 1.71 [1.04–2.81], P ¼ 0.035), LVMi per
g/m2 (HR 1.01 [1.00–1.01], P ¼ 0.037), statin treatment (HR
0.62 [0.40–0.98], P ¼ 0.039), and LVEDDi per mm/m2 (HR
1.04 [1. 00–1.08], P ¼ 0.040) (Table 4).
Kaplan–Meier estimates of survival in accordance
to the type of heart failure
Figure S1 demonstrates that Kaplan–Meier estimates of sur-
vival differ significantly between the different types of HF
with the best survival for patients with HFmrEF and lower
survival for HFpEF and HFrEF patients (P ¼ 0.024). Figure S2
shows similar results when multivariable analysis and Cox
Hazard proportional analysis were applied to picture survival.
Interaction of mild or moderate aortic
regurgitation and type of heart failure on
all‐cause mortality over the study period using
multivariable Cox regression analysis
ACM was higher in the group of AHF patients with AR (HR
1.75, [95% CI: 1.1–2.7], P ¼ 0.009) despite the overall more
favourable cardiovascular risk profile of this group. The final
model of multivariable Cox regression analysis with mild or
moderate AR as dependent variable included all variables of
the univariable Cox regression that showed at least very weak
evidence (P < 0.2) for an association with first, mild, or mod-
erate AR, second, 150 days’ ACM, and, third, type of HF (Ta-
ble 4). There was no evidence for a violation of the
proportional hazard assumption (P ¼ 0.369). Figure 1 illus-
trates the interaction of mild or moderate AR and the type
of HF on ACM. The hazard of HFpEF patients without AR
was used as reference. Within the HFpEF group, the presence
of AR increased the HR significantly when compared with the
absence of AR (HR: 2.17 [95% CI: 1.13–4.15], P ¼ 0.02). Com-
pared with the reference, we observed a more than twofold
increased hazard in HFrEF without AR (HR: 2.55 [95% CI:
1.33–4.87], P ¼ 0.005) and in HFrEF with AR (HR: 2.43 [95%
CI 1.26–4.69], P ¼ 0.008). The HR of HFmrEF patients without
AR was not different to respective HFpEF patients (HR: 0.2
[95% CI: 0.03–1.52], P ¼ 0.874), and presence of AR in
HFmrEF patients showed a trend towards increased ACM in
the HFmrEF group (HR: 7.11 [95% CI: 0.87–57.79],
P ¼ 0.067) (Figure 1).
Table 2 Biological characteristics of acute heart failure patients without or with mild or moderate aortic regurgitation
n All (n ¼ 505) Patients with AR (n ¼ 211) Patients without AR (n ¼ 294) P‐value
Haemoglobin (g/L) 505 123 [110–140] 123.0 [110–139] 123.0 [109–140] 0.923
Haematocrit (%) 503 37 [34–42] 38 [34–42] 37 [33–42] 0.845
RDW (%) 505 14.9 [13.9–16.2] 14.9 [13.9–16.3] 15.0 [13.9–16.2] 0.958
Leucocytes (G/L) 505 8.5 [6.8–10.7] 8.7 [7.0–11.1] 8.4 [6.7–10.3] 0.344
Glucose (mmol/L) 500 7.0 [6.0–9.2] 7.4 [6.0–10.1] 6.8 [5.9–8.4] 0.041
Creatinine (μmol/L) 504 108 [84–147] 106 [82–145] 110 [87–150] 0.130
Sodium (mmol/L) 504 139 [136–142] 139 [136–142] 140 [137–142] 0.715
Potassium (mmol/L) 504 4.3 [3.9–4.7] 4.3 [3.9–4.8] 4.3 [3.9–4.7] 0.301
Cholesterol (mmol/L) 391 3.9 [3.2–4.6] 3.8 [3.1–4.6] 4.0 [3.2–4.7] 0.123
AR, aortic regurgitation; RDW, red cell distribution width.
4 T. Abdurashidova et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12983
Tables S2 and S3 demonstrate demographics and clinical
parameters in HFpEF patients with or without mild to moder-
ate AR. HFpEF patients with mild to moderate AR had a
higher prevalence of female gender (57 [66.3%] vs. 70 pa-
tients [49.6%], P ¼ 0.014), while smoking (32 [37.2%] vs. 77
[55%] patients, P ¼ 0.009) and diabetes mellitus (21
[24.4%] vs. 53 [37.6%] patients, P ¼ 0.04) were less preva-
lent. Furthermore, diabetes was less often treated with insu-
lin (9 [10.5%] vs. 31 [22%], P ¼ 0.027). Biological parameters
were not significantly different between groups.
Discussion
This study adds to the current knowledge in AHF that AR of
mild or moderate severity is a determinant of short‐term
ACM in AHF patients with preserved LVEF. AR is highly prev-
alent in patients with preserved LVEF hospitalized for treat-
ment of AHF, suggesting that efforts to reduce the clinical
impact of AR have the potential to improve outcome in these
patients.
Prevalence of aortic regurgitation and chronic
heart failure in the general population and in
heart failure populations
Mild to moderate AR is in general not regarded as a major
clinical problem in patients with normal LVEF15,16 despite its
high prevalence in the age groups > 70 years.2,3 HF is also
highly prevalent in the elder age groups,4 making coincidental
occurrence of HF with AR likely. In fact, mild or moderate AR
was observed in 8.3% of ambulatory patients with HF symp-
toms in a community study involving 79.043 echocardio-
graphic studies.17 Further evidence supporting a role of AR
in HF derives from a retrospective population‐level epidemio-
logical study in Scotland, which showed that 25% of hospital-
ized patients with a diagnosis of AR had HF. The fact that only
3.3% of all these hospitalized AR cases had aortic valve re-
placement surgery suggests that the majority of the HF cases
had mild or moderate AR.7 Although not providing definite
proof of a pathophysiological role of mild to moderate AR,
the increase of the prevalence of AR in parallel with the clin-
ical severity of HF was nonetheless intriguing and the reason
for the present study. In fact, 42% of study participants in this
study had mild or moderate AR, which not only exceeds con-
siderably the respective prevalence reported elsewhere2,3,7,17
but may suggest likewise that the prevalence of mild or mod-
erate AR increases in parallel with the severity of HF.
Characteristics of the study population
The present study population included only 505 AHF patients;
we, therefore, discuss first whether the basic characteristics
of the study population such as portion of three HF types,
gender, age, and mortality permit broader application of
the study results.
A prominent characteristic of the present cohort is the 61%
prevalence of participants with mid‐range or preserved LVEF.
In fact, the prevalence of AHF patients with LVEF ≥ 40% was
lower in many previous AHF registries, in particular when
these studies had recruited participants during the first years
of the millennium.18 However, the more recent prospective,
multicentre Kyoto Congestive Heart Failure (KCHF) registry,
which had recruited AHF patients in the years 2014–2016, re-
ported a similar proportion of AHF patients with LVEF ≥ 40%
(61%).19 In addition, a similar proportion of AHF patients with
LVEF ≥ 40% (62%) was reported from the Get With The
Guidelines registry, which had recruited AHF patients in the
years 2005–2010.20 Of note, the number of AHF patients with
LVEF ≥ 40% had progressively increased between 2005 and
2010 from 48% to 53% in the latter registry21; in addition, a
similar trend had been reported for AHF admissions in the
Olmsted county where the percentage of patients with pre-
served LVEF increased from 38% to 54% in the years 1986
to 2002.22
With respect to gender distribution, the present study
population is comparable with that of other AHF registries,18
and the 56% of female patients in the HFpEF group corre-
spond to the female proportion reported in many HFpEF
Table 3 Echocardiographic characteristics of acute heart failure in patients with or without moderate aortic regurgitation
n All (n ¼ 505) Patients with AR (n ¼ 211) Patients without AR (n ¼ 294) P‐value
LVEDDi (mm/m2) 425 29.0 [26–33] 30.0 [27–34] 28.2 [25‐32] 0.004
LVMi (g/m2) 405 114 [90–136] 120 [93–144] 109 [86–132] 0.004
LADi (mm/m2) 414 25.0 [22‐28] 25.0 [23‐28] 25.0 [22‐28] 0.369
LVEF (%) 505 45.0 [30–60] 41.0 [30–60] 46.0 [30–60] 0.502
Mitral regurgitation (%) 504 417 (82.7) 192 (91.4) 225 (76.5) <0.001
Mitral stenosis (%) 505 10 (2.0) 4 (1.9) 6 (2.0) 0.908
Aortic regurgitation (%) 505 211 (41.8) 211 (100.0) 0 (0.0) <0.001
Aortic stenosis (%) 505 75 (14.9) 31 (14.7) 44 (15.0) 0.932
Tricuspid regurgitation (%) 503 395 (78.5) 178 (85.2) 217 (73.8) 0.002
LADi, indexed left atrial diameter; LVEDDi, left ventricular end‐diastolic diameter indexed to body surface; LVEF, left ventricular ejection
fraction; LVMi, left ventricular mass index.
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studies.23 Mean age was high in the present study population
but not different to reports from the KCHF or the Get With
The Guidelines registry19–21 although higher when compared
with AHF registries in the past.18 However, patients with
LVEF < 40% were younger than patients with LVEF ≥ 40%,
similar to other reports.20 Of note, 30 and 90 days’ mortality
of the present study population correspond to results
reported from Canadian Enhanced Feedback for Effective
Cardiac Treatment (EFFECT) and OPTIMIZE‐HF registry,
respectively.24 Last but not the least, the survival was best
in HFmrEF patients but lower in HFpEF and HFrEF patients,
corresponding to results reported from the Get With The
Guidelines registry.20 Altogether, this remarkable similarity
of the characteristics of the present study population with
other more contemporary AHF study cohorts suggests broad
applicability of the results of the present study.
The role of aortic regurgitation for all‐cause
mortality in acute heart failure patients
AR was in our study population associated with an increased
risk for ACM despite the short period of follow‐up. This asso-
ciation was observed against the background of a more
favourable cardiovascular risk profile of the AHF patients with
AR who were less often smokers or diabetics. However, we
did not observe the negative correlation between AR and
diabetes that had been reported from the Strong Heart
study.25
AR furthermore remained independently related with ACM
in AHF patients with preserved LVEF, raising the question of
why AR is of prognostic relevance in AHF with preserved LVEF
but not in AHF with either mid‐range or reduced LVEF. HFpEF
is characterized by disorder of muscular and hemodynamic
processes affecting propagation of blood flow during early di-
astole of the left ventricle. In the study participants with pre-
served LVEF and AR, we observed a numerically higher left
ventricular mass index and a numerically increased frequency
of mild or moderate tricuspid regurgitation. This combination
is compatible with an increased left ventricular end‐diastolic
pressure (LVEDP), suggesting that the small regurgitant vol-
ume of mild or moderate aortic valve insufficiency resulted
in a disproportionate increase of the LVEDP in the small and
stiff left ventricles of these patients. This effect may be even
worsen left ventricular dysfunction volume when patients al-
ready suffer from increased volume charge resulting from
mild or moderate MR. This pathophysiolgical concept can fur-
thermore explain why the small regurgitant volume is of
prognostic relevance in HFpEF patients but not in HFmrEF
or HFrEF patients. In fact, their LV end‐diastolic volume usu-
ally is larger, which should dampen the rise of the LVEDP with
a small aortic regurgitant volume.
However, it is also important to note that even a small
aortic regurgitant volume will result in a coronary steal with
a subsequently reduced intracoronary blood flow. The coro-
nary steal maybe of little relevance at rest but may
nonetheless induce subendocardial hypoxia with exertion
when the LVEDP increases disproportionally and the coronary
Table 4 Univariable analysis showing associations of parameters
with 150 days’ all‐cause mortality in all acute heart failure patients
Hazard ratio [95% CI] P‐value
Type of heart failure
AHFrEF 1.00 Baseline
AHFmrEF 0.38 [0.18–0.82] 0.013
AHFpEF 0.70 [0.45–1.08] 0.109
Demographic and clinical parameters
Age, per year 1.04 [1.01–1.06] 0.002
Male gender 0.99 [0.65–1.5] 0.950
BMI, per kg/m2 0.92 [0.89–0.96] <0.001
SBP admission, per mmHg 0.99 [0.98–0.99] <0.001
SBP discharge, per mmHg 0.98 [0.97–1.00] 0.004
DBP admission, per mmHg 0.99 [0.98–1.00] 0.053
DBP discharge, per mmHg 0.99 [0.98–1.01] 0.483
HR admission, per b.p.m. 1.00 [0.99–1.01] 0.982
HR discharge, per mmHg 1.00 [0.99–1.02] 0.685
Co‐morbidity
COPD 0.61 [0.32–1.18] 0.143
Smoking status 0.91 [0.60–1.38] 0.646
Hx of Afib/flutter 1.26 [0.82–1.93] 0.300
Hx of MI 0.91 [0.60–1.39] 0.667
Dyslipidaemia 0.44 [0.29–0.67] <0.001
Hypertension 0.64 [0.39–1.05] 0.075
Diabetes mellitus 0.76 [0.49–1.18] 0.223
QRS duration, per ms 1.00 [1.00–1.01] 0.122
Echocardiography
LVEDDi, per mm/m2 1.04 [1. 00–1.08] 0.040
LVMi, per g/m2 1.01 [1.00–1.01] 0.037
LADi, per mm/m2 1.03 [0.99–1.08] 0.188
LVEF, per % 0.99 [0.98–1.00] 0.212
Mitral regurgitation 1.33 [0.72–2.45] 0.358
Mitral stenosis 1.22 [0.30–4.94] 0.785
Aortic regurgitation 1.75 [1.15–2.66] 0.009
Aortic stenosis 1.32 [0.77–2.26] 0.320
Tricuspid regurgitation 1.14 [0.67–1.94] 0.618
Medical therapy
ICD 1.26 [0.58–2.72] 0.563
Pacemaker 1.86 [1.08–3.2] 0.025
Statin 0.62 [0.40–0.98] 0.039
Beta‐blocker 0.69 [0.45–1.06] 0.088
ACEI 0.95 [0.61–1.47] 0.818
ARB 0.71 [0.43–1.17] 0.176
ARNI — — —
MRA 1.71 [1.04–2.81] 0.035
Loop diuretic 0.99 [0.65–1.51] 0.953
Antidiabetic drug 0.54 [0.27–1.08] 0.083
Insulin 0.93 [0.53–1.62] 0.799
Laboratory values
Haemoglobin, per g/L 0.99 [0.99–1. 00] 0.32
Haematocrit, per % 0.99 [0.96–1.03] 0.598
RDW, per % 1.08 [1.01–1.15] 0.029
Leucocytes, per G/L 1.01 [0.97–1.04] 0.694
Glucose, per mmol/L 0.97 [0.91–1.04] 0.437
Creatinine, per μmol/L 1.00 [1.00–1.00] 0.133
Sodium, per mmol/L 1.00 [0.97–1.03] 0.844
Potassium, per mmol/L 0.98 [0.85–1.14] 0.824
Cholesterol, per mmol/L 0.95 [0.79–1.14] 0.571
BMI, body mass index; DBP, diastolic blood pressure; LVEDDi, left
ventricular end‐diastolic diameter index; LVMI, left ventricular mass
index; MRA, mineralocorticoid receptor antagonist; RDW, red cell
distribution width; SBP, systolic blood pressure.
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steal reduces the filling of the pre‐existing pathological micro-
circulation of the HFpEF heart at the same time.26
AR may furthermore disturb the diastolic vortex, which is
a swirling structure responsible for entering a significant
fraction of LV filling volume at no energetic or pressure
cost. In the normal heart, the vortex is responsible for en-
tering about 13% the filling volume, while this portion is re-
duced to 5% in hypertrophic cardiomyopathy.27 Impaired
generation of this swirling structure has also been shown
in HFpEF,28 and perturbation of the vortex function has
been associated with increased cardiovascular mortality
and rehospitalization.29 Biomechanical models of the left
ventricle have visualized that the regurgitant jet of mild or
moderate AR impedes vortex formation as a function of
its severity,30 suggesting that already a small regurgitant
volume should worsen the pre‐existing pathologic vortex
formation in patients with preserved LVEF. Support of this
hypothesis derives from the observation that mild AR after
transcatheter aortic valve replacement increased mortality
in patients with a baseline LVEF of 50 ± 13% as reported
from a series of patients operated at the Cleveland Clinic.31
Certainly, these patients do not represent the classical sta-
ble HF patient with preserved LVEF patient but nevertheless
provide evidence that new mild or moderate AR signifi-
cantly impacts on mortality within a time period of not
even 3 years.
Therapeutic implications
Improvement of AHF patients with preserved LVEF and AR
was associated with a decrease of systolic and diastolic blood
pressure and reduction of heart rate in addition. More re-
cently, independent association has been found between di-
astolic blood pressure or resting heart rate with mortality in
chronic moderate to severe AR.32 This investigation showed
that diastolic blood pressure < 70 mmHg and resting heart
rate > 60 b.p.m. increased ACM. Corresponding studies are
missing in AHF patients with mild to moderate AR but should
be useful for guidance of therapeutic management of these
patients. Careful monitoring of these parameters in the am-
bulatory setting may therefore prevent decompensation, in
particular in AHFpEF patients with AR. Whether implantation
of a hemodynamic monitoring device in the pulmonary circu-
lation is an option if traditional surveillance fails warrants
investigation.
Limitations
The relatively small study population and the mono‐centric
study design represent a methodological limitation with re-
spect to the applicability of the study results. Nevertheless,
study participants were recruited from consecutive patients
Figure 1 Illustration of the interaction of mild or moderate AR and type of heart failure on 150 days’ ACM using multivariable Cox regression. The haz-
ards in the different groups are compared with those of HFpEF without AR as baseline hazard. ACM, all‐cause mortality; AR, aortic regurgitation;
HFpEF, heart failure with preserved ejection fraction.
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presenting to the emergency department, and key character-
istics of the study participants are comparable with those of
other AHF cohorts. Furthermore, the post‐hoc study design
did not allow for retrospective distinction of the cause of
mortality in particular in those study participants followed
up by the 2005–2009 cohort. However, the short‐term
follow‐up and the careful exclusion of AHF patients with ad-
verse prognosis related to co‐morbidity suggests that case fa-
tality was likely due to cardiovascular cause. In the
acknowledgement of these limitations, the study results of
this study remain therefore hypothesis generating.
Conclusions
The results of this study suggest that AR of mild or moderate
severity is of prognostic relevance in patients with preserved
LVEF and hospitalization for treatment of AHF. This observa-
tion merits attention because coincidence of AR and HF is fre-
quent in the elderly. Therefore, better understanding of the
interaction between AR and LV dysfunction in HFpEF patients
is necessary and will help to reduce the negative impact of
mild or moderate AR in these patients.
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